#Japan #Minato #Smith & Nephew #TRIGEN MAX #Tibial Fractures

Smith & Nephew Unveils Next-Generation TRIGEN MAX TIBIA System

Smith & Nephew, a leader in advanced medical technology, has announced the launch of the TRIGEN MAX TIBIA system, designed specifically for treating tibial shaft fractures in Japan. This next-generation implant builds on over 20 years of clinical success from the TRIGEN series, emphasizing enhanced anatomical compatibility, multi-directional fixation, and improved operability during surgical procedures.

Background: Expanding Indications and Challenges of Intramedullary Nails

The tibial shaft is among the most frequently fractured long bones, with a high likelihood of open fractures due to its proximity to thin soft tissue. In cases of adult tibial shaft fractures, intramedullary nails (IM nails) are typically the first line of treatment. Recently, the use of IM nails has expanded to accommodate fractures at both the proximal and distal ends of the tibia, addressing a broader range of injury types.

Three Innovations of the TRIGEN MAX TIBIA System

1. Anatomical Screw Trajectory with Left and Right Specific Designs
The TRIGEN MAX TIBIA utilizes separate designs for left- and right-sided nails, allowing screws to follow an anatomical trajectory. This design optimizes fracture fixation while considering surrounding soft tissue, reducing the risk of complications during surgery.

2. Variable Angle Locking Technology
This innovative nail features a variable angle locking mechanism for the proximal and distal screw holes. Surgeons can now choose flexible screw insertion angles based on fracture morphology, which expands their options for fixation strategies.

3. Revamped Distal Screw Configuration
The distal design excludes AP direction screws, significantly lowering the risk of interfering with surrounding soft tissues, including nerves, blood vessels, and tendons. Additionally, the new trajectory for screws targeting the posterior fragments permits fixation from multiple directions, enhancing the overall stabilization of the fracture.

Smith & Nephew is committed to leveraging its extensive experience in trauma care to reinforce its portfolio of solutions, including intramedullary nails and external fixators. The company's goal is to continue contributing to the advancement of trauma care in Japan through innovative product offerings.

About the Product

• - Product Name: TRIGEN MAX Tibia Nail System
• - Approval Number: 30800BZX00038000

Smith & Nephew emphasizes that the TRIGEN MAX brand is part of its trademark portfolio.

Company Overview

Smith & Nephew Inc., based in Tokyo, is driven by the mission to enhance the quality of life through technology. This commitment, articulated as “Life Unlimited,” informs all operations, with over 18,000 employees worldwide dedicated to developing innovative solutions in orthopedics, wound care, sports medicine, and ENT. Founded in Hull, England, in 1856, Smith & Nephew operates in more than 100 countries and projects a revenue of $5.8 billion for the year 2025. As a member of the FTSE 100, the company embodies a strong commitment to quality and innovation in the healthcare sector.

For more information, visit Smith & Nephew's website and the TRIGEN MAX product page.

This article serves to inform stakeholders within Japan regarding the latest initiatives from Smith & Nephew and is designed for media distribution, not intended for the promotion of specific products.